ABSTRACT: Chronic myelogenous leukemia (CML) is associated with a translocation of the protooncogene c-abl from chromosome 9 to chromosome 22, where it fuses to proximal exons of the bcr gene. The expression of the hybrid gene bcr-abl is regulated by the bcr promoter and results in a translation product with high tyrosine kinase activity. In most CML cases, one of two abl promoters (Pa) is nested within the bcr-abl transcription unit, but appears to be usually silent. Recently, de novo methylation of the Pa region and its correlation with disease progression were reported. As these previous studies were limited to the use of methylation-sensitive restriction endonucleases, our aim here was to obtain a complete map of methylcytosines and its variants in CML patients and in model cell lines. To achieve this, bisulfite conversion of cytosines (but not methylcytosines) to uracils in genomic DNA was employed. After modification, the region of interest was PCR-amplified and the products were cloned and sequenced. The results show methylation at a high level and in a homogenous pattern in the BV173 cell line, corresponding to the translocated abl alleles. Variant methylation observed in K562 cells correlates with multiple bcr-abl loci and an intact chromosome 9. Patients that were methylation-positive in restriction analysis showed sporadic and heterogenous occurrence of methylcytosines in bisulfite modification assays. Corresponding results were obtained using a quantitative Southern analysis of the extent of methylation. We conclude that restriction analysis combined with PCR is able to find rare cases of hypermethylation, e.g., for diagnostic purposes, but does not reflect the dominating level of methylation in Ph-positive cells.
INTRODUCTION
Chronic myelogenous leukemia (CML) is a hematological stem cell disorder characterized by excessive proliferation of the myeloid lineage. It is the first human malignancy in which an association of activation of a cellular oncogene with chromosomal translocation was shown. CML is characterized in more than 90% of patients by the Philadelphia (Ph) chromosome, which involves a reciprocal translocation between the c-abl gene on chromosome 9 and the breakpoint cluster region (bcr) locus on chromosome 22 [t(9;22) (q34.11; q11.1)] (1, 2). The bcr-abl mRNA, which is under the transcriptional control of the bcr promoter, is translated into a 210-kDa tyrosine kinase (p210 bcr-abl ). Compared with the endogenous cabl, p210
bcr-abl has increased kinase activity and binds significantly more strongly to cytoskeletal actin. This affects the regulation of cell adhesion, cell survival, and proliferation (3) (4) (5) , all of which are thought to play a crucial role in the pathogenesis of CML.
Clinically, CML is characterized by a tripha-sic course: a chronic phase, an accelerated phase, and a blast crisis. An affected stem cell gives rise to myeloid or lymphoid progenitors, which lose their capacity for terminal differentiation in the late phases of the disease (6 -8) . Disease progression is highly variable, and knowledge of the molecular changes resulting in evolution from the chronic phase to the accelerated phase and blastic crisis could thus be useful for optimization of therapy. The search for such molecular events heralding blastic transformation resulted in the observation of de novo methylation of a CpG island surrounding one of the abl gene promoters (Pa). In most cases, this promoter and the coding region of the gene is translocated intact to the bcr locus, but the translocated promoter appears to be silent in model cell lines (9) . The tempting idea that Pa methylation in CML is associated with disease progression was first presented and demonstrated by Zion et al. (9) , and later the hypomethylating effect of interferon therapy on the Pa promoter was reported by the same group (10) . However, a recent independent study of this issue has shown the lack of prognostic significance of Pa methylation for survival or response to interferon therapy (11) .
All the three above-mentioned studies (9 -11) were limited to examination of the cleavage of genomic DNA by methylation-sensitive restriction endonuclease(s). Consequently, their results can neither show the complete distribution of methylcytosines (mC) over the region, nor distinguish between the presence of a single or multiple methylation patterns in a given patient or cell line. As these factors might be a source of the above discrepant conclusions, we have addressed this issue using both conventional restriction enzyme/ PCR assays and genomic sequencing after bisulfite modification of DNA. The bisulfite technique uses a specific conversion of cytosines (but not methylcytosines) in genomic DNA to uracils (12) . The modified DNA strands of the region of interest are then PCR-amplified and the products cloned. Subsequent sequencing of a number of clones from the same reaction shows the sequence-specific methylation pattern and its variants in a given source material. Parallel use of both techniques shows their limitations for practical use and suggests that caution is necessary in assessing the role of increased Pa methylation in the course of CML.
MATERIALS AND METHODS

Genomic DNA Preparation
Ph-positive CML cell lines BV173 (13)and K562 (14) were used. Samples of bone marrow from CML patients were collected during a 2-year period. DNA was extracted from the mononuclear cell fraction using QIAamp DNA Mini Kit (QIA-GEN)
DNA Sequence of the Pa Region
The fragment of the Pa region which was analyzed is shown in Fig. 1 . The positions of primers used in both kinds of analyses are described below, and restriction sites decisive for the results of restriction enzyme/PCR assays are shown.
Restriction Enzyme/PCR Analysis of DNA Methylation
The technique described by Zion et al. (9) was used. Briefly, 200-ng aliquots of genomic DNA were digested in parallel 10-l reactions with the restriction enzymes MspI, HpaII, and SacII (all from NEB) in NEB buffers. To achieve complete digestion, restriction enzymes were added in two 5-unit aliquots; the second addition was after 2 h of digestion and the total time of digestion was 6 h. Aliquots (2.5 l) of reaction mixtures were used as template for PCR. In parallel, PCRs with nondigested template DNA were run on each patient sample as a positive control. 25 l of PCR mixture contained 50 ng of template DNA, 50 mM Tris-HCl (pH 8.8), 20 mM (NH 4 ) 2 SO 4 , 10% dimethyl sulfoxide, 1% tetramethyl ammonium chloride, 1 mM MgCl 2 , 0.2 mM each dNTP, 0.5 M primer CG25 (5Ј-ACCTTCCAGATAA-CAGCTGGAGGAC-3Ј) and 0.5 M primer CG20 (5Ј-CGGGGGGGCGCGCGGGCCGA-3Ј) (Fig. 1) . The following temperature conditions were used on a Perkin-Elmer 480 thermal cycler: initial denaturation 97°C/10 min; addition of 1.25 U AmpliTaq polymerase (Perkin-Elmer) at 84°C; 26 cycles (95°C/1 min (t), 59°C/1 min and 72°C/1 min); final extension 72°C/7 min. Products of PCR were analyzed on 2% NuSieve agarose (FMC), stained with SybrGreen I (Molecular Dynamics), and visualized either on a UV transilluminator or a STORM 860 Phosphofluoroimager (Molecular Dynamics).
Positive and negative controls were analyzed in parallel with each set of samples. As a positive control, DNA of K562 or BV173 cells was used. For a negative control, a cloned fragment of the promoter region was prepared: this fragment was amplified from genomic DNA of a healthy donor in a 25-l reaction mixture containing 200 ng of DNA, 50 mM Tris-HCl (pH 8.8), 20 mM (NH 4 ) 2 SO 4 , 10% dimethyl sulfoxide, 2 mM MgCl 2 , 0.2 mM each dNTP, 0.5 M forward primer Abl-1KF (5Ј-CGCTTCCAGGCGGAGA-AA-3Ј) and 0.5 M reverse primer Abl-2KR (5Ј-CTACTCAGCCCAACCCGT-3Ј) (see Fig. 1 
Mapping of Methylcytosine Positions Using Bisulfite Genomic Sequencing
Genomic DNA isolated from cell cultures or bone marrow was digested with restriction endonuclease HindIII (NEB), purified with a QIAquick PCR purification kit (Qiagen GmbH), and dissolved in distilled water. For the bisulfite modification (12, 15) , an aliquot of 2 g of DNA in 90 l of H 2 O was alkali-denatured with 10 l of 3 M NaOH for 15 min at 37°C. Bisulfite reagent was prepared by dissolving 2.65 g of NaHSO 3 (sodium bisulfite) and 2.65 g of Na 2 S 2 O 5 (sodium metabisulfite) in 10 ml of H 2 O immediately before use. The pH was adjusted to 4.8 -5.0 with 10 M NaOH. 968 l of the bisulfite solution and 57 l of 10 mM hydroquinone were added to the denatured DNA. The solution was gently mixed and immediately overlaid with 150 l of mineral oil and incubated at 55°C for 16 h in the dark. Samples were then dialyzed for 3 ϫ 1 h against 1000 vol of 0.5 mM hydroquinone/5 mM sodium acetate pH 5.2, 3 ϫ 1 h against 0.5 mM sodium acetate, pH 5.2, and finally 3 ϫ 1 h and 1 ϫ 16 h against distilled water. All dialyses were performed in the dark at 4°C. The sample volume was then reduced on a SpeedVac (Savant) to about 100 l and DNA was purified using A QIAprep Spin Miniprep kit (Qiagen, GmbH). DNA was eluted in 90 l of redistilled water and desulfonated for 15 min at 37°C after addition of Three microliters of primary PCR product was used as template DNA for nested PCR, which was run under the same conditions as the primary PCR with the nested primers Abl-2MF (5Ј-GGGAATGTTAGGGGTTTT-3Ј) and Abl-1MR (5Ј-CAACCCACCAACT-TCAAA-3Ј). The above primers were designed so that the original CpG dinucleotides were avoided, if possible (a single CpG is present in the middle of the primers Abl-4MF and Abl-2M), as a prerequisite for their neutral behavior with respect to variant products of the modification procedure.
PCR products were separated by agarose electrophoresis, excised and extracted from agarose, and cloned using a TOPO TA cloning kit (Invitrogen) into the pCRII-TOPO vector (Invitrogen). The construct was used for transformation of TOP10 cells (Invitrogen), and white colonies were screened for the presence of an insert of the desired length either by PCR or by restriction enzyme digestion of plasmid DNA. About 20 clones (coming) from a single modification reaction were sequenced on an ABI PRISM 310 genetic analyzer (Perkin-Elmer).
Control reactions were performed using the fragment of the promoter region cloned in pBluescriptII SK(Ϫ) vector (see above). The plasmid was linearized and about 100 ng were methylated in vitro using SssI methylase (NEB). Two modification reactions were then performed under the above conditions, using 40 ng of methylated plasmid or 40 ng of a 1:1 mixture of methylated and unmethylated plasmid. As a carrier, DNA of phage was used in a fifty-fold excess in both reactions. Further steps (modification reaction, PCR, cloning and sequencing) were performed in the same way as in experimental samples.
Quantitative Southern Analysis of the Extent of Methylation
To quantify the level of methylation within the region analyzed previously by RE/PCR and bisulfite genomic sequencing, the methylation state of the SacII restriction site in this region (see Fig. 1 ) was probed. DNA samples (12 g) were first digested for 6 h with 120 units of StyI (NEB) in NEB3 reaction buffer to cut out the 295-bp region of interest. After heat inactivation of the enzyme and ethanol precipitation of DNA, samples were digested with SacII (NEB4 buffer, 6 h, 10 U/g). SacII digests DNA to completion only if the two CpG sites in its recognition region are unmethylated. DNA samples were electrophoresed on a 2% NuSieve agarose gel (FMC), transferred to Biodyne Plus membrane (Pall Gelman Sciences) and hybridized with a 32 P-labeled probe. As a probe, the 162-bp fragment of the region downstream from the SacII site ( Fig. 1 ) was used. Thus, the hybridization signal detects either a 295-bp (in the case of a methylated SacII site) or a 194-bp fragment (in the absence of methylation). Results were visualized using a phosphorimager STORM 860 (Molecular Dynamics) and quantified by ImageQuant Software (Molecular Dynamics) as the ratio of the 295-bp signal to the sum of the 194-and 295-bp signals.
RESULTS
Methylation State Determined Using Restriction Enzyme/PCR Assay
Genomic DNA of cell lines BV173 and K562, as well as DNA of several patients at different stages of CML, were tested by the restriction enzyme/PCR assay. The results obtained are summarized in Table 1 . It follows from these results that methylation is absent in patients with other hematological malignancies without bcr/abl translocations, and in about one third of CML patients 
FIRST PAGE PROOF in the chronic phase. In two of the latter patients, transition to a methylation-positive state was observed in successive bone marrow samples. In a single case (from the chronic phase), different results of SacII and HpaII reactions were observed. Most patients from the chronic phase and all those from the accelerated phase and blast crisis showed positive methylation. Methylation was observed reproducibly in both BV173 and K562 cell lines, which were then used as positive controls.
Methylation State Determined by Bisulfite Genomic Sequencing
Bisulphite modification reactions were performed with six substrate DNAs from the following sources: reactions 1 and 2, bone marrow of CML patients 1 and 2, respectively (blast crisis stage, strongly positive in the previous restriction enzyme/PCR assay); reaction 3, BV173 cells; reaction 4, K562 cells; reactions 5 and 6, in vitro methylated control plasmid and a 1:1 mixture of methylated and unmethylated control plasmid, respectively (see Materials and Methods).
Sequencing of clones (coming) from control reactions 5 and 6 showed that all 10 clones originating from reaction 5 were methylated at 77-96% of the total 49 CpGs available in the Pa region (excluding the primer sequences). Further, the conserved presence of dcm methylation was found originating from cultivation of the control plasmid in the XL1-Blue Escherichia coli strain prior to the modification reaction. Thus, dcm methylation in control reactions provides a useful marker of the method's reliability, which is independent of the efficiency of in vitro SssI methylation. From 20 randomly-chosen clones from reaction 6, 9 showed a methylation pattern similar to clones from reaction 5, while the remaining 11 clones displayed only the dcm methylation. Thus, these control reactions established the efficiency and reliability of the modification procedure, and the absence of any strong bias in downstream procedures (cloning and PCR), for discriminating either previously methylated or unmethylated source DNA sequences.
The alignment of clones derived from reaction 3 (BV173 DNA) shows a high level and a relatively homogeneous pattern of CpG methylation. (see Table 2 ). This is confirmed by direct sequencing of PCR products prior to cloning, resulting in a consensus methylation pattern (Table 2, The results of methylation analysis of clones from K562 cells (reaction 4) are aligned in Table  3 . Apparently, the methylation pattern is heterogeneous compared with that of BV173 cells. No methylcytosines are present in 8 clones, and three clones (k562-5, k562-7, and k562-19) contain only 1-3 methylcytosines. In the remaining 9 clones, the level of methylation and conservation of methylcytosine positions is relatively high, although lower than in BV173 clones. From the positions listed above which were found to be hypomethylated in BV173 clones, three appear to be conservatively methylated among these 9 K562 clones.
Clones derived from CML patients in blast crisis (reactions 1 and 2) showed either a total absence of methylation, or the presence of only a few methylcytosines (1-3 per clone) (see Tables 4 
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Note. Numbers are assigned to each of 49 CpGs available within the analyzed region according to their succession and presence (ϩ) or absence (Ϫ) of methylcytosine is marked.
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TABLE 5
Pattern of CpG Methylation in Clones Originated from the Pa-Region of Patient 2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Quantitative Southern Analysis of Methylation State
Hybridization signals shown in Fig. 2 were evaluated as the percentage of methylated SacII sites. While BV173 (lane 2) and K562 (lane 3) showed 100 and 46% of methylation, respectively, in both CML patients in blast crisisidentical to those tested previously by bisulfite genomic sequencing (lanes 4 and 5) only about 10% of SacII sites were methylated. No methylated fraction was detected in CML patient in chronic phase, AML patient without bcr-abl translocation and normal donor.
DISCUSSION
The role of aberrant de novo methylation in cancer-related genes has recently been the subject of many studies. However, the results of these studies are sometimes discrepant, and most groups have limited their analyses to the use of methylation-sensitive restriction endonuclease cleavage. This was also the case in studies of the CpG island surrounding the Pa promoter of the translocated abl allele in the "classical" oncogene bcr-abl (9 -11) . To elucidate this discrepancy, we applied the technique of bisulfite genomic sequencing (12) to the region in parallel with the use of methylation-sensitive restriction enzymes.
Having established the reliability of the method in control reactions, the technique was applied to the CML cell line BV173 as a model and revealed a homogeneous hypermethylation of the Pa region. This shows that both translocated abl alleles are equivalent with respect to their methylation state. This result correlates with the positivity of restriction enzyme/PCR assays as well as with the absence of a Pa-originated transcript found in a previous study (9) . Besides methylation in CpG doublets, both cytosines in the CpCpG triplet (at CpG No. 13) were found to be methylated in 10% of the clones. Although we cannot exclude, due to its rare occurrence, that this may be a consequence of incomplete modification, it is consistent with earlier reports of the capability of mammalian cells to methylate cytosines in CpNpG (16) and about the biological function of this kind of methylation (inhibition of Sp1 binding to the Sp1 binding site in the CpG island promoter of the retinoblastoma gene) (17) .
A different result was obtained in clones from cell line K562, where half of the clones show absence of methylation. This can be explained by the presence of an intact abl allele in this cell line and correlates with the presence of both normal abl and bcr-abl transcripts in these cells (9) . However, assuming a ratio of bcr-abl to intact abl loci, and bearing in mind the absence of bias of the procedure demonstrated in control reaction 6 (see above), one would expect a prevalence of methylated clones. The result obtained thus suggests that a fraction of the translocated alleles lacks methylation. We speculate that this may be a consequence of instability of the copy number of bcr-abl fusion genes in K562 cells: extensive amplification of bcr-abl fusion genes has been 
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FIRST PAGE PROOF observed in K562 cells resulting in 22-24 copies per cell (18) , although in earlier reports (19, 20) a lesser number of copies was found. It appears that the copy number of bcr-abl fusion genes increases with time (18) and that some newly amplified copies may not share the hypermethylated state of the original bcr-abl copy residing on the Ph chromosome.
While the results of bisulfite genomic sequencing obtained with control plasmids and with both cell lines are essentially in agreement with restriction enzyme/PCR assays, CML patients' samples showed an extremely low level of methylation using the bisulfite technique. None of the clones analyzed showed a methylation pattern corresponding to a positive restriction enzyme/ PCR assay. Assuming the presence of a nontranslocated allele in each cell [karyotype of patient 1: 46, XY, t(9;22) (18), karyotype of patient 2: 46,XX, t(9;22) (20)], 6 -8 clones should have shown methylation of the Pa region of the bcr-abl fusion gene. If there were a homogeneous hypermethylation, we would have expected approximately this number of clones bearing a methylation pattern similar to BV173 cells. However, besides clones lacking any methylcytosines, we obtained about the same number of clones showing only 1-3 methylcytosines scattered along the sequence. This result may be interpreted as evidence that the methylation pattern is not uniform within the Ph-positive fraction of cells of a given patient in blast crisis, and the fraction of Phpositive cells bearing a hypermethylated Pa region is too small to be represented within the 20 clones analyzed, although it is sufficient to produce positive results in restriction enzyme/PCR assays. This interpretation is supported by the results of quantitative Southern evaluation of the methylation of the SacII site within the region analyzed previously by RE/PCR and genomic sequencing.
Apparently, the hypermethylated fraction may be sufficient to drive the progress of the disease. By analogy to the detection of minimal residual disease, the restriction enzyme/PCR technique is the most useful for detection of the minor fraction of cells bearing a hypermethylated Pa region against the high background of Ph-negative and hypomethylated Ph-positive cells. On the other hand, bisulfite genomic sequencing shows the spectrum of methylation patterns present in a given sample, the complexity of which is limited only by the number of analyzed clones.
The mechanism by which DNA methylation affects gene expression is only partially understood. The correlation of DNA methylation with gene silencing and with condensed chromatin structure has been known for more than a decade (21, 22) . It has been proposed that transcription is not repressed by DNA methylation directly, but via methylcytosine-binding proteins (MeCP1, MeCP2) (23, 24) . A direct causal relationship between DNA methylation-dependent transcriptional silencing and the modification of chromatin structure has been found only recently: one of the proteins that binds methylated DNA, MeCP2, exists in a complex with histone deacetylase (25) . As deacetylation of histone tails in nucleosomes promotes formation of an inactive (condensed) chromatin structure, methylated CpG dinucleotides within promoter regions may target histone deacetylase and in this way direct inhibition of transcription (25, 26) .
In the case of the bcr-abl fusion gene, there is apparently some kind of competition between the bcr promoter and the translocated Pa promoter. The phenotypic effect of translocation (the genetic change) can be partially compensated by this competition for a certain period of time, corresponding possibly to the chronic phase. The onset of methylation (and silencing) of the Pa promoter is possibly the key epigenetic change, which is decisive for takeover of transcriptional control by the bcr promoter, thus promoting progression of the disease.
